Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Dibutyl-phthalate exposure from mesalamine medications and serum thyroid hormones in men.

Nassan FL, Korevaar TIM, Coull BA, Skakkebæk NE, Krawetz SA, Estill M, Hait EJ, Korzenik JR, Ford JB, De Poortere RA, Broeren MA, Moss AC, Zoeller TR, Hauser R.

Int J Hyg Environ Health. 2018 Aug 28. pii: S1438-4639(18)30549-2. doi: 10.1016/j.ijheh.2018.08.008. [Epub ahead of print]

PMID:
30170956
2.

Mucosal Gene Expression in Pediatric and Adult Patients With Ulcerative Colitis Permits Modeling of Ideal Biopsy Collection Strategy for Transcriptomic Analysis.

Ouahed J, Gordon W, Canavan JB, Zhou H, Du S, von Schack D, Phillips K, Wang L, Dunn WA 3rd, Field M, Friel S, Griffith A, Evans S, Tollefson S, Carrellas M, Cao B, Merker A, Bousvaros A, Shouval DS; BCH IBD Center; BWH Crohn’s and Colitis Center, Hung K, Lepsy C, Afzelius L, Korzenik JR, Snapper SB.

Inflamm Bowel Dis. 2018 Jul 31. doi: 10.1093/ibd/izy242. [Epub ahead of print]

PMID:
30085215
3.

Suicidal Behavior Among Hospitalized Adults With Inflammatory Bowel Disease: A United States Nationwide Analysis.

Marchioni Beery RM, Barnes EL, Nadkarni A, Korzenik JR.

Inflamm Bowel Dis. 2017 Dec 19;24(1):25-34. doi: 10.1093/ibd/izx005.

PMID:
29272476
4.

The Practical Pros and Cons of Complementary and Alternative Medicine in Practice: Integrating Complementary and Alternative Medicine into Clinical Care.

Winter RW, Korzenik JR.

Gastroenterol Clin North Am. 2017 Dec;46(4):907-916. doi: 10.1016/j.gtc.2017.08.013. Review.

PMID:
29173531
5.

A probabilistic pathway score (PROPS) for classification with applications to inflammatory bowel disease.

Han L, Maciejewski M, Brockel C, Gordon W, Snapper SB, Korzenik JR, Afzelius L, Altman RB.

Bioinformatics. 2018 Mar 15;34(6):985-993. doi: 10.1093/bioinformatics/btx651.

6.

The Burden of Hospital Readmissions among Pediatric Patients with Inflammatory Bowel Disease.

Barnes EL, Kochar B, Long MD, Martin CF, Crockett SD, Korzenik JR, Kappelman MD.

J Pediatr. 2017 Dec;191:184-189.e1. doi: 10.1016/j.jpeds.2017.08.042. Epub 2017 Oct 14.

PMID:
29037795
7.

A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and serum reproductive hormones in men.

Nassan FL, Coull BA, Skakkebaek NE, Andersson AM, Williams MA, Mínguez-Alarcón L, Krawetz SA, Hall JE, Hait EJ, Korzenik JR, Ford JB, Moss AC, Hauser R.

Environ Res. 2018 Jan;160:121-131. doi: 10.1016/j.envres.2017.09.025. Epub 2017 Oct 1.

PMID:
28978458
8.

Association of urinary phenolic compounds, inflammatory bowel disease and chronic diarrheal symptoms: Evidence from the National Health and Nutrition Examination Survey.

de Silva PS, Yang X, Korzenik JR, Goldman RH, Arheart KL, Caban-Martinez AJ.

Environ Pollut. 2017 Oct;229:621-626. doi: 10.1016/j.envpol.2017.06.023.

PMID:
28689150
9.

Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database.

Barnes EL, Kochar B, Long MD, Kappelman MD, Martin CF, Korzenik JR, Crockett SD.

Inflamm Bowel Dis. 2017 Jun;23(6):875-881. doi: 10.1097/MIB.0000000000001121.

10.

Clinical patient registry recruitment and retention: a survey of patients in two chronic disease registries.

Solomon DH, Shadick NA, Weinblatt ME, Frits M, Iannaccone C, Zak A, Korzenik JR.

BMC Med Res Methodol. 2017 Apr 17;17(1):59. doi: 10.1186/s12874-017-0343-3.

11.

High Dietary Intake of Specific Fatty Acids Increases Risk of Flares in Patients With Ulcerative Colitis in Remission During Treatment With Aminosalicylates.

Barnes EL, Nestor M, Onyewadume L, de Silva PS, Korzenik JR; DREAM Investigators.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1390-1396.e1. doi: 10.1016/j.cgh.2016.12.036. Epub 2017 Jan 18.

12.

Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases.

Winter RW, Collins E, Cao B, Carrellas M, Crowell AM, Korzenik JR.

Aliment Pharmacol Ther. 2017 Mar;45(5):653-659. doi: 10.1111/apt.13936. Epub 2017 Jan 10.

13.

Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery.

Barnes EL, Goldin A, Winter RW, Collins E, Cao B, Carrellas M, Crowell AM, Korzenik JR.

Dig Dis Sci. 2016 Nov;61(11):3261-3269. Epub 2016 Sep 17.

14.

A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease.

Nassan FL, Coull BA, Skakkebaek NE, Williams MA, Dadd R, Mínguez-Alarcón L, Krawetz SA, Hait EJ, Korzenik JR, Moss AC, Ford JB, Hauser R.

Environ Int. 2016 Oct;95:120-30. doi: 10.1016/j.envint.2016.08.006. Epub 2016 Aug 26.

15.

Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database.

Barnes EL, Beery RM, Schulman AR, McCarthy EP, Korzenik JR, Winter RW.

Inflamm Bowel Dis. 2016 Sep;22(9):2229-37. doi: 10.1097/MIB.0000000000000899.

16.

Crohn's Cartography: Mapping Disease Patterns and Trajectories Using the Lémann Index-Are We Finding Our Way?

Marchioni Beery RM, Korzenik JR.

J Clin Gastroenterol. 2016 Jul;50(6):441-4. doi: 10.1097/MCG.0000000000000539. No abstract available.

PMID:
27159423
17.

Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles.

Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, Bry L, Clish CB, Alm E, Korzenik JR.

Aliment Pharmacol Ther. 2016 Jun;43(11):1142-53. doi: 10.1111/apt.13616. Epub 2016 Apr 18.

18.

Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer.

Lennerz JK, van der Sloot KWJ, Le LP, Batten JM, Han JY, Fan KC, Siegel CA, Srivastava A, Park DY, Chen JH, Sands BE, Korzenik JR, Odze RD, Dias-Santagata D, Borger DR, Khalili H, Iafrate AJ, Lauwers GY.

Int J Colorectal Dis. 2016 May;31(5):973-982. doi: 10.1007/s00384-016-2574-x. Epub 2016 Mar 30.

PMID:
27026089
19.

A Case Report of Improvement in Crohn's Disease-related Symptoms Following Participation in a Comprehensive Mind-Body Program.

Dossett ML, Korzenik JR, Baim M, Denninger JW, Mehta DH.

Glob Adv Health Med. 2016 Jan;5(1):122-5. doi: 10.7453/gahmj.2015.118. Epub 2016 Jan 1.

20.

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.

Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, Sauk J, Giallourakis C, Garber J, Hamilton MJ, Tomczak M, Makrauer F, Burakoff RB, Levine J, de Silva P, Friedman S, Ananthakrishnan A, Korzenik JR, Yajnik V.

Inflamm Bowel Dis. 2015 Dec;21(12):2879-85. doi: 10.1097/MIB.0000000000000561.

21.

An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease.

Zhang S, Ermann J, Succi MD, Zhou A, Hamilton MJ, Cao B, Korzenik JR, Glickman JN, Vemula PK, Glimcher LH, Traverso G, Langer R, Karp JM.

Sci Transl Med. 2015 Aug 12;7(300):300ra128. doi: 10.1126/scitranslmed.aaa5657.

22.

Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease.

Allegretti JR, Borges L, Lucci M, Chang M, Cao B, Collins E, Vogel B, Arthur E, Emmons D, Korzenik JR.

Inflamm Bowel Dis. 2015 Nov;21(11):2583-9. doi: 10.1097/MIB.0000000000000537.

23.

Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection.

Allegretti JR, Korzenik JR, Hamilton MJ.

J Vis Exp. 2014 Dec 8;(94). doi: 10.3791/52154.

24.

Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort.

Juillerat P, Sokol H, Froehlich F, Yajnik V, Beaugerie L, Lucci M, Burnand B, Macpherson AJ, Cosnes J, Korzenik JR.

Inflamm Bowel Dis. 2015 Jan;21(1):60-70. doi: 10.1097/MIB.0000000000000225.

PMID:
25517594
25.

Impaired innate immune function associated with fecal supernatant from Crohn's disease patients: insights into potential pathogenic role of the microbiome.

Meelu P, Marin R, Clish C, Zella G, Cox S, Yajnik V, Nguyen DD, Korzenik JR.

Inflamm Bowel Dis. 2014 Jul;20(7):1139-46. doi: 10.1097/MIB.0000000000000081.

PMID:
24892965
26.

SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease.

Fowler SA, Ananthakrishnan AN, Gardet A, Stevens CR, Korzenik JR, Sands BE, Daly MJ, Xavier RJ, Yajnik V.

J Crohns Colitis. 2014 Aug;8(8):845-51. doi: 10.1016/j.crohns.2014.01.003. Epub 2014 Jan 24.

27.

Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts.

Khalili H, Ananthakrishnan AN, Konijeti GG, Liao X, Higuchi LM, Fuchs CS, Spiegelman D, Richter JM, Korzenik JR, Chan AT.

BMJ. 2013 Nov 14;347:f6633. doi: 10.1136/bmj.f6633.

28.

Marijuana use patterns among patients with inflammatory bowel disease.

Ravikoff Allegretti J, Courtwright A, Lucci M, Korzenik JR, Levine J.

Inflamm Bowel Dis. 2013 Dec;19(13):2809-14. doi: 10.1097/01.MIB.0000435851.94391.37.

29.

Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals.

Juillerat P, Wasan SK, Fowler SA, Friedman S, Pabby VK, Coukas JA, Barto AE, Pellish R, Germansky KA, Cheifetz AS, Korzenik JR, Farraye FA, Yajnik V.

Inflamm Bowel Dis. 2013 Oct;19(11):2457-63. doi: 10.1097/MIB.0b013e3182a32a0d.

PMID:
23962896
30.

A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis.

Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Korzenik JR, Fuchs CS, Willett WC, Richter JM, Chan AT.

Gastroenterology. 2013 Nov;145(5):970-7. doi: 10.1053/j.gastro.2013.07.050. Epub 2013 Aug 2.

31.

Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease.

Knutson CG, Mangerich A, Zeng Y, Raczynski AR, Liberman RG, Kang P, Ye W, Prestwich EG, Lu K, Wishnok JS, Korzenik JR, Wogan GN, Fox JG, Dedon PC, Tannenbaum SR.

Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):E2332-41. doi: 10.1073/pnas.1222669110. Epub 2013 Jun 10.

32.

Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases.

Oxford EC, Nguyen DD, Sauk J, Korzenik JR, Yajnik V, Friedman S, Ananthakrishnan AN.

Am J Gastroenterol. 2013 Jul;108(7):1123-9. doi: 10.1038/ajg.2013.20. Epub 2013 Feb 19.

33.

Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease.

Papa E, Docktor M, Smillie C, Weber S, Preheim SP, Gevers D, Giannoukos G, Ciulla D, Tabbaa D, Ingram J, Schauer DB, Ward DV, Korzenik JR, Xavier RJ, Bousvaros A, Alm EJ.

PLoS One. 2012;7(6):e39242. doi: 10.1371/journal.pone.0039242. Epub 2012 Jun 29.

34.

Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease.

Juillerat P, Schneeweiss S, Cook EF, Ananthakrishnan AN, Mogun H, Korzenik JR.

Aliment Pharmacol Ther. 2012 Aug;36(3):239-47. doi: 10.1111/j.1365-2036.2012.05173.x. Epub 2012 Jun 5.

35.

Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis.

Ananthakrishnan AN, Korzenik JR, Hur C.

Inflamm Bowel Dis. 2013 Jan;19(1):37-44. doi: 10.1002/ibd.22951.

PMID:
22416019
36.

Barriers to enrollment in inflammatory bowel disease randomized controlled trials: an investigation of patient perspectives.

Ravikoff JE, Cole EB, Korzenik JR.

Inflamm Bowel Dis. 2012 Nov;18(11):2092-8. doi: 10.1002/ibd.22872. Epub 2012 Jan 12.

PMID:
22241674
37.

Higher predicted vitamin D status is associated with reduced risk of Crohn's disease.

Ananthakrishnan AN, Khalili H, Higuchi LM, Bao Y, Korzenik JR, Giovannucci EL, Richter JM, Fuchs CS, Chan AT.

Gastroenterology. 2012 Mar;142(3):482-9. doi: 10.1053/j.gastro.2011.11.040. Epub 2011 Dec 9.

38.

Validation of the functional assessment of chronic illness therapy-fatigue (FACIT-F) in patients with inflammatory bowel disease.

Tinsley A, Macklin EA, Korzenik JR, Sands BE.

Aliment Pharmacol Ther. 2011 Dec;34(11-12):1328-36. doi: 10.1111/j.1365-2036.2011.04871.x. Epub 2011 Oct 17.

39.

Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.

Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR.

Aliment Pharmacol Ther. 2011 Dec;34(11-12):1318-27. doi: 10.1111/j.1365-2036.2011.04866.x. Epub 2011 Sep 29. Review.

40.

Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis.

Ananthakrishnan AN, Hur C, Korzenik JR.

Dig Dis Sci. 2012 Feb;57(2):472-80. doi: 10.1007/s10620-011-1896-3. Epub 2011 Sep 11.

PMID:
21909990
41.

Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis.

Ananthakrishnan AN, Hur C, Juillerat P, Korzenik JR.

Am J Gastroenterol. 2011 Nov;106(11):2009-17. doi: 10.1038/ajg.2011.237. Epub 2011 Jul 26.

PMID:
21788991
42.

Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.

Cullen G, Bader C, Korzenik JR, Sands BE.

Gut. 2012 Mar;61(3):385-91. doi: 10.1136/gutjnl-2011-300256. Epub 2011 Jul 13.

PMID:
21757451
43.

LRRK2 is involved in the IFN-gamma response and host response to pathogens.

Gardet A, Benita Y, Li C, Sands BE, Ballester I, Stevens C, Korzenik JR, Rioux JD, Daly MJ, Xavier RJ, Podolsky DK.

J Immunol. 2010 Nov 1;185(9):5577-85. doi: 10.4049/jimmunol.1000548. Epub 2010 Oct 4.

44.

Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis.

Zella GC, Hait EJ, Glavan T, Gevers D, Ward DV, Kitts CL, Korzenik JR.

Inflamm Bowel Dis. 2011 May;17(5):1092-100. doi: 10.1002/ibd.21460. Epub 2010 Sep 15.

PMID:
20845425
45.

Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent.

Subramanian S, Yajnik V, Sands BE, Cullen G, Korzenik JR.

Inflamm Bowel Dis. 2011 Jan;17(1):99-104. doi: 10.1002/ibd.21370.

PMID:
20629183
46.

Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease?

Bordeianou L, Stein SL, Ho VP, Dursun A, Sands BE, Korzenik JR, Hodin RA.

Surgery. 2011 Jan;149(1):72-8. doi: 10.1016/j.surg.2010.03.009.

PMID:
20434748
47.

Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy.

Engelbrektson A, Korzenik JR, Pittler A, Sanders ME, Klaenhammer TR, Leyer G, Kitts CL.

J Med Microbiol. 2009 May;58(Pt 5):663-70. doi: 10.1099/jmm.0.47615-0.

PMID:
19369530
48.

Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists.

Hait EJ, Barendse RM, Arnold JH, Valim C, Sands BE, Korzenik JR, Fishman LN.

J Pediatr Gastroenterol Nutr. 2009 Jan;48(1):61-5. doi: 10.1097/MPG.0b013e31816d71d8.

PMID:
19172125
49.

Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire.

Lam MY, Lee H, Bright R, Korzenik JR, Sands BE.

Inflamm Bowel Dis. 2009 Apr;15(4):599-607. doi: 10.1002/ibd.20803.

PMID:
19023897
50.

Diverticulitis: new frontiers for an old country: risk factors and pathogenesis.

Korzenik JR; NDSG.

J Clin Gastroenterol. 2008 Nov-Dec;42(10):1128-9. doi: 10.1097/MCG.0b013e318188adb1. Review.

PMID:
18936649

Supplemental Content

Loading ...
Support Center